Postępy Dermatologii i Alergologii

Full text

4/2026 vol. 43
Review paper

Lebrikizumab for the treatment of atopic dermatitis: a systematic review and meta-analysis of randomised controlled trials

Jiaxi Tang 1
,
Zijing Ruan 1
,
Yuezhou Huang 1

  1. Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Adv Dermatol Allergol 2026; XLIII (4): 355-363

DOI: https://doi.org/10.5114/ada.2026.164303
Data publikacji online: 2026/09/14
Article file
PDIiA Lebrikizumab.pdf
  1. Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci 2021; 22: 4130.
  2. Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol 2025; 155: 1124-32.
  3. Afshari M, Kolackova M, Rosecka M, et al. Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol 2024; 15: 1361005.
  4. Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician 2020; 101: 590-8.
  5. Robinson L, Strowd LC. American Academy of Dermatology Guidelines for managing atopic dermatitis. Adv Exp Med Biol 2024; 1447: 217-25.
  6. Missaoui S, Gaadi A, Oussama K, et al. The primary mechanisms underlying atopic dermatitis. Tunis Med 2025; 103: 65-72.
  7. Mohammad S, Karim MR, Iqbal S, et al. Atopic dermatitis: pathophysiology, microbiota, and metabolome – a comprehensive review. Microbiol Res 2024; 281: 127595.
  8. Fyhrquist N, Yang Y, Karisola P, et al. Endotypes of atopic dermatitis. J Allergy Clin Immunol 2025; 156: 24-40.
  9. Wienholtz NK, Vestergaard C, Deleuran M, et al. Atopisk eksem [Atopic dermatitis]. Ugeskr Laeger 2025; 187: V10240722.
  10. Okragly AJ, Ryuzoji A, Wulur I, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther 2023; 13: 1535-47.
  11. Johnston L, Poelman S, Metelitsa A. Lebrikizumab for moderate-to-severe atopic dermatitis. Skin Therapy Lett 2025; 30: 1-7.
  12. Guttman-Yassky E, Sun Z, Mena LR, et al. Lebrikizumab rapidly lowers inflammatory biomarkers with clinical correlations in moderate-to-severe atopic dermatitis. Dermatol Ther 2025; 15: 2595-614.
  13. Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2023; 24: 753-64.
  14. Warren RB, de Bruin-Weller M, Tsianakas A, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage). Br J Dermatol 2025; 193: 876-88.
  15. Katoh N, Tanaka A, Takahashi H, et al. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). Curr Med Res Opin 2025; 41: 1-12.
  16. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023; 188: 740-8.
  17. Silverberg JI, Guttman-Yassky E, Thaçi D, et al.; ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388: 1080-91.
  18. Simpson EL, Gooderham M, Wollenberg A, et al.; ADhere Investigators. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol 2023; 159: 182-91.
  19. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020; 156: 411-20.
  20. Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018; 78: 863-71.
  21. Soung J, Ständer S, Gutermuth J, et al. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. J Dermatolog Treat 2024; 35: 2329240.
  22. Yosipovitch G, Lio PA, Rosmarin D, et al. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. Br J Dermatol 2024; 190: 289-91.
  23. Yosipovitch G, de Bruin-Weller M, Wiseman M, et al. Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol 2025; 50: 1188-92.
  24. Yosipovitch G, Lio PA, Rosmarin D, et al. Lebrikizumab improved itch symptoms and reduced itch interference on sleep over 52 weeks in patients with moderate-to-severe atopic dermatitis in two phase 3 trials. Dermatology 2025; 241: 325-35.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications